The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers

被引：5

作者：

Flores-Funes, Diego ^{[1
,4
]}

Aguilar-Jimenez, Jose ^{[1
,4
]}

Martinez-Galvez, Maria ^{[2
,4
]}

Jose Ibanez-Ibanez, Maria ^{[3
]}

Carrasco-Gonzalez, Luis ^{[1
,4
]}

Ignacio Gil-Izquierdo, Jose ^{[2
,4
]}

Luis Aguayo-Albasini, Jose ^{[1
,4
]}

机构：

[1] Hosp Gen Univ JM Morales Meseguer, Serv Cirugia Gen, Murcia, Spain

[2] Hosp Gen Univ JM Morales Meseguer, Serv Radiodiagnost, Murcia, Spain

[3] Hosp Gen Univ JM Morales Meseguer, Med Nucl, Murcia, Spain

[4] Univ Murcia, Fac Med, IMIB Arrixaca, Campus Excelencia Int Mare Nostrum, Murcia, Spain

来源：

CIRUGIA ESPANOLA | 2020年 / 98卷 / 09期

关键词：

Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy; Targeted axillary dissection; Wire location; Intraoperative ultrasound; Radioioidine seed; Ferromagnetic seed; TUMOR-LOCALIZATION; WIRE LOCALIZATION; CLIPPED NODE; THERAPY; IDENTIFICATION; MARKING; SURGERY; BIOPSY; FEASIBILITY; ACCURACY;

D O I：

10.1016/j.ciresp.2020.03.012

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Targeted axillary dissection (TAD) consists of a new axillary staging technique that combines sentinel lymph node biopsy (SLNB) and clipped lymph node biopsy (CLNB) in the same surgery, in order to re-stage patients with breast cancer and positive axillary lymph nodes undergoing neoadjuvant chemotherapy (NAQT). Prior to the NAQT, the affected lymph node is punctured and a solid marker is left inside echo-guided, in order to biopsy it in the subsequent surgery. There are numerous types of markers: metallic (steel, titanium or polyglycolic acid clips), radioiodine or ferromagnetic seeds, which differ in the method of location (wire, gamma-detection or magnetic probe). The aim of this study is to perform a systematic review about the current status of the TAD, as well as to explain the different techniques and types of axillary marking, based on the current available evidence. (C) 2020 AEC. Published by Elsevier Espana, S.L.U. All rights reserved.

引用

页码：510 / 515

页数：6

共 50 条

[21] Sentinel lymph node biopsy for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy.
Kinoshita, T
Fukutomi, T
Akashi-Tanaka, S
Terada, K
Takasugi, M
Shimizu, C
Ando, M
Katsumata, N
Fujiwara, Y
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S41 - S41
[22] Axillary lymph node recurrence and prognosis of avoiding axillary lymph node dissection by sentinel lymph node biopsy after neoadjuvant chemotherapy
Kajiwara, Y.
Kin, T.
Fujihara, M.
Yoshimura, Y.
Ito, M.
Ohtani, S.
EUROPEAN JOURNAL OF CANCER, 2016, 57 : S75 - S75
[23] Targeted axillary dissection after neoadjuvant chemotherapy
Steer, Susanne
Grosse, Regina
Zentgraf, Holger
Thomssen, Christoph
CANCER RESEARCH, 2020, 80 (04)
[24] Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results
Flores-Funes, Diego
Aguilar-Jimenez, Jose
Martinez-Galvez, Maria
Jose Ibanez-Ibanez, Maria
Carrasco-Gonzalez, Luis
Ignacio Gil-Izquierdo, Jose
Asuncion Chaves-Benito, Maria
Ayala-De La Pena, Francisco
Nieto-Olivares, Andres
Luis Aguayo-Albasini, Jose
SURGICAL ONCOLOGY-OXFORD, 2019, 30 : 52 - 57
[25] AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy
Banys-Paluchowski, M.
Stickeler, E.
de Boniface, J.
Gentilini, O.
Thill, M.
Hartmann, S.
Fasching, P. A.
Huebner, H.
Krawczyk, N.
Blohmer, J-U
Solbach, C.
Untch, M.
Kuehn, T.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E20 - E21
[26] AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy
Banys-Paluchowski, M.
Stickeler, E.
de Boniface, J.
Gentilini, O.
Thill, M.
Hartmann, S.
Fasching, P. A.
Huebner, H.
Krawczyk, N.
Blohmer, J. U.
Solbach, C.
Untch, M.
T, Kuehn
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E93 - E94
[27] Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy
Gurleyik, Gunay
Aksu, Sibel Aydin
Aker, Fugen
Tekyol, Kubra Kaytaz
Tanrikulu, Eda
Gurleyik, Emin
ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2021, 100 (06) : 305 - 312
[28] Validity of omission of axillary lymph node dissection after neoadjuvant chemotherapy for node-positive primary breast cancer
Matsumoto, Akiko
Umemoto, Yasuko
Tsukahara, Daisuke
Jinno, Hiromitsu
CANCER RESEARCH, 2020, 80 (04)
[29] Nomogram Predicting Axillary Lymph Node Dissection Omission After Neoadjuvant Chemotherapy for Node-positive Breast Cancer
Seki, Hirohito
Ishiguro, Yuki
Makino, Akitsugu
Yamaguchi, Kei
Imoto, Shigeru
ANTICANCER RESEARCH, 2024, 44 (11) : 5131 - 5138
[30] Sentinel lymph node biopsy as an alternative to axillary lymph node dissection after neoadjuvant chemotherapy
不详
EJC SUPPLEMENTS, 2006, 4 (02): : 73 - 73

← 1 2 3 4 5 →